Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine
暂无分享,去创建一个
Xiwei Wu | E. Manuel | D. Diamond | N. Ebelt | T. Rogers | Heidi Contreras | M. D. Salazar | Soojin Park | Joybelle Martinez | Jenny Nguyen | F. Chiuppesi | F. Wussow | V. Nguyen | Teodora I. Kaltcheva | Mindy Kha | A. Iniguez | Y. Shostak | Qiao Zhou | T. Kang | Roman Levytskyy
[1] D. Burton,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.
[2] A. Sette,et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.
[3] Y. Hu,et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial , 2020, The Lancet.
[4] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[5] R. Baric,et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.
[6] Daniel W. Kulp,et al. Immunogenicity of a DNA vaccine candidate for COVID-19 , 2020, Nature Communications.
[7] Barney S. Graham,et al. Rapid COVID-19 vaccine development , 2020, Science.
[8] Xinquan Wang,et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals , 2020, Immunity.
[9] X. Tang,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[10] A. Iwasaki,et al. The potential danger of suboptimal antibody responses in COVID-19 , 2020, Nature Reviews Immunology.
[11] J. Bloom,et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays , 2020, bioRxiv.
[12] N. Lurie,et al. Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.
[13] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[14] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[15] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[16] A. Nademanee,et al. Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients , 2020, Annals of Internal Medicine.
[17] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[18] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[19] G. Whittaker,et al. Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting. , 2019, Journal of visualized experiments : JoVE.
[20] D. Diamond,et al. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice , 2018, Journal of Virology.
[21] S. Lederman,et al. Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments , 2018, PloS one.
[22] H. Yin,et al. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab , 2017, Oncoimmunology.
[23] P. Earl,et al. Generation of Recombinant Vaccinia Viruses , 2017, Current protocols in protein science.
[24] I. Aldoss,et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. , 2017, Blood.
[25] G. Sutter,et al. Modified Vaccinia Virus Ankara , 2016, Advances in Virus Research.
[26] A. Herrmann,et al. Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex , 2014, PLoS pathogens.
[27] M. Carroll,et al. Recombinant MVA vaccines: dispelling the myths. , 2013, Vaccine.
[28] S. Gilbert. Clinical development of Modified Vaccinia virus Ankara vaccines. , 2013, Vaccine.
[29] A. Herrmann,et al. A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces Broadly Neutralizing Antibodies in Rhesus Macaques , 2012, Journal of Virology.
[30] J. Peiris,et al. Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway , 2011, Journal of Virology.
[31] A. Mayr,et al. Attenuierung von virulentem Hühnerpockenvirus in Zellkulturen und Eigenschaften des attenuierten Virus , 2010 .
[32] Zhongde Wang,et al. Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines , 2009, Vaccine.
[33] P. Earl,et al. Elucidating and Minimizing the Loss by Recombinant Vaccinia Virus of Human Immunodeficiency Virus Gene Expression Resulting from Spontaneous Mutations and Positive Selection , 2009, Journal of Virology.
[34] A. Goesmann,et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. , 2007, The Journal of general virology.
[35] J. von Einem,et al. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. , 2006, BioTechniques.
[36] D. Tscharke,et al. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines , 2005, The Journal of experimental medicine.
[37] W. Britt,et al. Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B Causes Durable Immunity and Neutralizing Antibodies against Multiple Strains of Human Cytomegalovirus , 2004, Journal of Virology.
[38] L. Casper,et al. Dispelling the Myths , 2002 .
[39] F. Falkner,et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.
[40] B. Moss,et al. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. , 1997, Virology.
[41] B. Moss,et al. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. , 1996, Vaccine.
[42] B. Moss,et al. Nonreplicating vaccinia vector efficiently expresses recombinant genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[43] F. Falkner,et al. Construction of chimeric vaccinia viruses by molecular cloning and packaging. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[44] M. Merchlinsky. Mutational analysis of the resolution sequence of vaccinia virus DNA: essential sequence consists of two separate AT-rich regions highly conserved among poxviruses , 1990, Journal of virology.
[45] E. Paoletti,et al. Protective immunity against avian influenza induced by a fowlpox virus recombinant. , 1988, Vaccine.
[46] B. Moss,et al. Molecular cloning and sequence of the concatemer junction from vaccinia virus replicative DNA. Viral nuclease cleavage sites in cruciform structures. , 1988, Journal of molecular biology.
[47] G. McFadden,et al. Efficient resolution of replicated poxvirus telomeres to native hairpin structures requires two inverted symmetrical copies of a core target DNA sequence , 1987, Journal of virology.
[48] G. McFadden,et al. Replication and resolution of cloned poxvirus telomeres in vivo generates linear minichromosomes with intact viral hairpin termini , 1986, Journal of virology.
[49] B. Moss,et al. Resolution of linear minichromosomes with hairpin ends from circular plasmids containing vaccinia virus concatemer junctions , 1986, Cell.
[50] H. Birnboim,et al. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. , 1979, Nucleic acids research.
[51] P. Barry,et al. Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. , 2018, Journal of virological methods.
[52] Gregory A. Smith,et al. En passant mutagenesis: a two step markerless red recombination system. , 2010, Methods in molecular biology.
[53] B. Moss,et al. Structure and replication of vaccinia virus telomeres. , 1983, Cold Spring Harbor symposia on quantitative biology.
[54] K. Malicki,et al. [Attenuation of virulent fowl pox virus in tissue culture and characteristics of the attenuated virus]. , 1966, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B.